Reimbursement policy of Lucatinib

The country and Guangdong Province have included the anti-tumor drug rukotinib tablets in the drug list of version 20 19, which is required to be implemented from June 5438+1 October1day in 2020. Our city will do a good job in landing the drug list on time and include Lucotinib tablets in the scope of outpatient treatment for specific diseases. Before the state adopted the policy, the calculation method of reimbursement was that the total amount of drugs was reimbursed in proportion, and it didn't matter whether the drugs were dismantled or not. According to the payment standard issued by China, drugs are reimbursed according to tablets. For example, the payment standard for one tablet is 0.5 yuan, which some hospitals don't know, but the prescription is made by the box. For example, a box of 10 yuan, 9.5 yuan is conceited. I learned from the medical insurance Q group that many private clinics don't understand policies, and many of them are recruited.

General public hospitals purchase the drugs that won the bid and the original drugs that failed to win the bid (unless the original drugs won the bid). The most puzzling thing for patients is that the original research drugs (imported drugs) that have not won the bid feel more and more "expensive", which seems to be different from the media propaganda (compared with the original research anticancer drugs that have been greatly reduced in price after being included in the medical insurance catalogue).

Take atorvastatin (Lipitor) as an example. During the "4+7" pilot period, the state has set the policy direction, and the medical insurance reimbursement will be less and less year by year. If the price is not significantly reduced by 2022, it will be almost at your own expense. The country did this because the previous reimbursement methods were not detailed enough (the more expensive, the more reimbursement), which led to the "patent cliff" that generally appeared abroad after the patent of the original drug expired (as follows). Now, with the support of the system and technology, the original drug and generic drug have been treated fairly, which promoted fair competition, and at the same time prompted manufacturers to reduce prices and patients to switch to the winning drug. In the drug list of two diseases, the payment standard of the original drug is also relatively low, such as nifedipine controlled-release tablets (Baixintong), the hospital price is 3.4 yuan, and the payment standard is 1.09 12 yuan, and the reimbursement is greatly reduced compared with before. It can be seen that it is close to the treatment of non-bid original drugs adopted by the state, and it is only a matter of time before all high-sugar chronic drugs are brought into the state (for example, several drugs such as acarbose and glimepiride in the catalogue of two diseases were included in the second batch of national drugs adopted after the publication of the "two diseases" document, and the payment standard was changed from provincial to bid).